Gene Therapy
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Unlock global gene therapy market insights. Stay ahead on regulatory approvals, clinical trials, and investment opportunities in this cutting-edge biotech sector.
Showing 13–24 of 35 articles
ASGCT 2024: Gene Therapy Advancements Day 1 Roundup
ASGCT 2024: Day 1 Key Takeaways in Gene Therapy Advancements
ASGCT 2026: Gene Therapy Manufacturing Innovations Emerge
ASGCT: Manufacturing Innovations Take Center Stage
ASGCT 2024: Gene Therapy Advancements Take Center Stage
Opus Genetics' OPGx-LCA5 Gene Therapy Accepted Into FDA's Rare Disease Evidence Program
Restore Vision Reports Positive Safety Data for RV-001 Gene Therapy in Retinitis Pigmentosa Trial
Expression Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for Hemophilia A Stem Cell Therapy
Regeneron Announces Free Gene Therapy Otarmeni for Rare Hearing Loss in U.S. Government Agreement
Wave Life Sciences WVE-007 Phase 2a Trial Gets FDA Approval for Obesity and Type 2 Diabetes Treatment
Intellia Therapeutics Submits FDA Application for Lonvo-Z, First CRISPR Gene Therapy for Hereditary Angioedema
Intellia Therapeutics Achieves First-Ever Positive Phase 3 Results for In Vivo Gene Editing with Lonvoguran Ziclumeran in Hereditary Angioedema